四氯噻嗪 | 4267-05-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻二嗪
• 中文名称: 四氯噻嗪
• 中文别名: 三氯甲氯氢噻嗪
• 英文名称: teclothiazide
• 英文别名: 6-Chlor-3-trichlormethyl-7-sulfamoyl-1.2.4-benzothiadiazin-1.1-dioxyd；6-Chlor-3-trichlormethyl-1,1-dioxy-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazin；6-Chlor-7-sulfamoyl-3-trichlormethyl-3,4-dihydro-1,2,4-benzothiodiazin-1,1-dioxid；6-Chlor-3-trichlormethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxid；6-chloro-1,1-dioxo-3-trichloromethyl-1,2,3,4-tetrahydro-1λ⁶-benzo[1,2,4]thiadiazine-7-sulfonic acid amide；6-Chlor-7-sulfamoyl-3-trichlormethyl-1,1-dioxy-3,4-dihydro-2H-1,2,4-benzothiadiazin；6-Chlor-7-sulfamoyl-3-trichlormethyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxid；6-chloro-1,1-dioxo-3-(trichloromethyl)-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide
• CAS: 4267-05-4
• 化学式: C₈H₇Cl₄N₃O₄S₂
• 分子量: 415.105
• InChiKey: GUTZRTRUIMWMJZ-UHFFFAOYSA-N

物化性质

• 熔点：
  300-303° (Close); mp 287° (Novello)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  135
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  5-氯-2,4-二磺酰胺基苯胺 、 1,1,1-三氯-2,2-二乙氧基乙烷 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 四氯噻嗪
  参考文献：
  名称：

  Klosa,J.; Voigt,H., Journal fur praktische Chemie (Leipzig 1954), 1962, vol. 16, p. 264 - 276

  摘要：

  DOI：

文献信息

• Dibenzyl Amine Compounds and Derivatives
  申请人：Chang George

  公开号：US20070213371A1

  公开（公告）日：2007-09-13

  Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  二苯基胺化合物及其衍生物，含有这种化合物的药物组合物以及使用这种化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他一些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病在某些哺乳动物，包括人类。
• [EN] DUAL-ACTING ANTIHYPERTENSIVE AGENTS<br/>[FR] AGENTS ANTIHYPERTENSIFS À DOUBLE ACTION
  申请人：THERAVANCE INC

  公开号：WO2009035543A1

  公开（公告）日：2009-03-19

  The invention relates to compounds having the formula: (I) wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及具有以下公式的化合物：(I) 其中：Ar、r、R3、Z、X和R5-7按说明书定义，或其药用可接受盐。这些化合物具有AT1受体拮抗活性和中性内肽酶抑制活性。本发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• NEPRILYSIN INHIBITORS
  申请人：Hughes Adam D.

  公开号：US20130330366A1

  公开（公告）日：2013-12-12

  In one aspect, the invention relates to compounds having the formula XII: where R a , R b , R 2 , R 7 , and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一方面，本发明涉及具有公式XII的化合物： 其中R a ，R b ，R 2 ，R 7 和X如说明书中所定义，或其药用可接受的盐。所述的化合物是具有中性粒细胞弹性蛋白酶抑制活性的化合物的前药。在另一方面，本发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• [EN] NEPRILYSIN INHIBITORS<br/>[FR] INHIBITEURS DE LA NÉPRILYSINE
  申请人：THERAVANCE BIOPHARMA R & D IP LLC

  公开号：WO2015116786A1

  公开（公告）日：2015-08-06

  In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一方面，本发明涉及具有公式（I）的化合物：其中R1-R6定义如说明书中所述，或其药用可接受的盐。这些化合物具有中性粒细胞弹性蛋白酶抑制活性。在另一方面，本发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• SUBSTITUTED AMIDE COMPOUNDS
  申请人：Pfizer Inc.

  公开号：US20140315928A1

  公开（公告）日：2014-10-23

  The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

  本发明涉及替代酰胺化合物，含有这种化合物的药物组合物以及利用这种化合物降低血浆脂质水平，如LDL-胆固醇和甘油三酯，并据此治疗由高水平的LDL-胆固醇和甘油三酯加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中的应用。